Ranbaxy to market RAN-Cefprozil for Canada

New Delhi, Apr 12: Ranbaxy Laboratories Ltd (RLL), today announced that it has received approval from Canadian authorities to manufacture and market RAN-Cefprozil tablets and powder.

''This further adds to our expanding generic product portfolio which will have benefits of offering an affordable generic alternative to the brand that will now be accessible to all Canadians,'' Ranbaxy Pharmaceuticals Canada Inc (RPCI) President Bill Abboud said.

Cefprozil tablets and powder are indicated for treatment of upper respiratory tract infections, uncomplicated skin and urinary tract infections.

RPCI based in Mississauga, Canada, is a wholly-owned subsidiary of RLL.

It is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.

UNI